To the full analysis
Buyback calculator for Corcept Therapeutics
Corcept Therapeutics stock: key metrics
CORTCorcept Therapeutics had an operating margin of 5.9% and a return on invested capital (ROIC) of 15.3% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 100.0% | −8,701.4% | −8,460.2% |
| 2007 | 100.0% | −2,540.5% | −2,401.0% |
| 2008 | 100.0% | −9,420.6% | −9,598.6% |
| 2009 | 100.0% | −69,827.6% | −69,537.9% |
| 2010 | no data | no data | no data |
| 2011 | no data | no data | no data |
| 2012 | 97.2% | −1,096.8% | −1,150.5% |
| 2013 | 98.6% | −400.7% | −444.3% |
| 2014 | 96.7% | −104.0% | −118.2% |
| 2015 | 97.3% | −6.8% | −12.7% |
| 2016 | 97.5% | 12.5% | 10.0% |
| 2017 | 97.8% | 33.2% | 81.1% |
| 2018 | 97.9% | 35.6% | 30.0% |
| 2019 | 98.2% | 36.4% | 30.7% |
| 2020 | 98.4% | 36.2% | 30.0% |
| 2021 | 98.6% | 34.0% | 30.7% |
| 2022 | 98.7% | 28.0% | 25.2% |
| 2023 | 98.7% | 22.2% | 22.0% |
| 2024 | 98.4% | 20.3% | 20.7% |
| 2025 | 98.3% | 5.9% | 13.1% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | −100.0% | no data | −100.0% |
| 2007 | −78.5% | −91.4% | −65.2% |
| 2008 | −100.0% | −98.2% | −100.0% |
| 2009 | −91.3% | −82.0% | −82.3% |
| 2010 | −100.0% | no data | −100.0% |
| 2011 | −93.0% | −91.1% | −81.2% |
| 2012 | −61.6% | −44.7% | −38.4% |
| 2013 | −100.0% | −43.8% | −72.9% |
| 2014 | 200.0% | −50.4% | −90.6% |
| 2015 | −34.6% | −7.1% | −12.3% |
| 2016 | 19.7% | 19.9% | 11.8% |
| 2017 | 67.6% | 115.6% | 58.5% |
| 2018 | 27.3% | 93.9% | 24.2% |
| 2019 | 25.4% | 107.4% | 22.8% |
| 2020 | 20.3% | 112.3% | 18.5% |
| 2021 | 29.9% | 94.2% | 26.6% |
| 2022 | 20.2% | 87.7% | 17.4% |
| 2023 | 20.9% | 87.1% | 17.1% |
| 2024 | 20.6% | 54.2% | 16.6% |
| 2025 | 15.4% | 15.3% | 11.9% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 4 Nov 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.